Copy of APP Podcast Playlist

Panel Discussion - Infection And Urologic Implants

This educational series is supported by independent educational grants from AstraZeneca and Merck.

CME Available: https://auau.auanet.org/node/31223

Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care. 

Upon completion of this activity, participants will be able to:
1. Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition.
2. Discuss the current clinical trials associated with PARP inhibitors.
3. Describe the patient populations associated with each trial.
4. State the clinical outcomes for each trial.

PARP Inhibitors: Assessing the Clinical Trial Landscape

Multidisciplinary Discussion On Fertility, Hypogonadism & Sexual Function For Testis Cancer Patients

How to Manage a 65 Year Old Man with Bothersome LUTS and Underactive Bladder

This educational series is supported by independent educational grants from AstraZeneca and Merck.

CME Available: https://auau.auanet.org/node/31224

Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care. 

Upon completion of this activity, participants will be able to:
1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.
2. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer.
3. Discuss the impact of shared-decision making on patient and on patient-clinician communication.
4. Describe how telemedicine can be successfully incorporated into the care continuum of patients with advanced prostate cancer.

PARP Inhibitors: Best Practices In Advanced Prostate Cancer Care In The Community

This podcast was funded by and developed in collaboration with AstraZeneca.

Learning Objectives:
At the conclusion of this activity, participants will be able to: 
1. Identify the role of genomic testing in men with different stages of prostate cancer.
2. Recognize the need for collaboration with genetic counselors for optimal genetic evaluation tailored to an individual prostate cancer patient.
3. Explain the criteria for genomic testing of prostate cancer patients across the disease spectrum, current NCCN testing guidelines, difference between germline and somatic testing, different testing modalities currently available gene panels, options for testing these men, and appropriate timing for testing.
4. Interpret the results of genomic testing, implications for shared‐decision with patients based on the test results, and impact on novel therapies and personalized treatment for prostate cancer care.
5. Apply best practices and lessons learned for operationalizing testing and testing workflows in urology practices.

For more information: https://auau.auanet.org/content/genomic-testing-prostate-cancer-podcast-podcast-2021

Genomic Testing in Prostate Cancer

This podcast was funded by and developed in collaboration with AstraZeneca.

Learning Objectives:
At the conclusion of this activity, participants will be able to:
1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.
2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.
3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.
4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.

For more information: https://auau.auanet.org/content/overview-parpi-adverse-event-management-podcast-2021

An Overview of PARPi & Adverse Event Management

Incorporating Genomic Testing For Prostate Cancer into Your Practice (2021)

CME Available: https://auau.auanet.org/node/31455

ACKNOWLEDGEMENTS
Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.

At the conclusion of the activity, participants will be able to:
1. Describe the seminal validation studies for prostate cancer genomic testing.
2. List the different prognostic endpoints provided by various genomic tests.
3. Identify appropriate genomic testing based on a patient's unique clinical characteristics.
4. Review the AUA and NCCN guidelines for genomic testing for prostate cancer.

AUA2021 Kick Off Weekend: Incorporating Genomic Testing For Prostate Cancer into Your Practice

Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider (2021)

CME Available: https://auau.auanet.org/node/31450

ACKNOWLEDGEMENTS
Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.

At the conclusion of the activity, participants will be able to:
1. Explain the mechanism of checkpoint inhibitors.
2. Describe historical and novel treatments for systemic prostate cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
3. Describe historical and novel treatments for systemic bladder cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
4. Describe historical and novel treatments for systemic kidney cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.

AUA2021 Kick Off Weekend: Chemotherapy and Immunotherapy for the Urologist and APP

Contemporary Pharmacotherapy for OAB 2021: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2021)

CME Available: https://auau.auanet.org/node/31460

ACKNOWLEDGEMENTS
Support provided by independent educational grants from AbbVie, Astellas, Medtronic, Urovant Sciences, Inc.

At the conclusion of the activity, participants will be able to:
1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).
2. Review the principles of physiology and pharmacotherapy for currently available agents, including the anti-muscarinics and beta-3 agonists and combination therapy.
3. Express the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
5. Discuss potential future pharmacological pathways and therapies for OAB.

AUA2021 Kick Off Weekend: Contemporary Pharmacotherapy for OAB 2021

Designed to encourage high quality, evidence-based testing and care of patients with bladder cancer, this podcast episode focuses on Genetic Testing for Bladder Cancer. Listen today to discover the differences between molecular markers and genetic testing, how genetic testing for bladder cancer is performed and current considerations of genetic findings.

Co-Host: Neal Shore, MD, FACS

Acknowledgement: 
This podcast was funded by Janssen Oncology.

For more information: https://auau.auanet.org/content/genetic-testing-bladder-cancer-podcast-2021

Genetic Testing in Bladder Cancer

This educational series is supported by independent educational grants from Olympus Corporation of the Americas and Teleflex.

CME Available: https://auau.auanet.org/node/32295

At the conclusion of this activity, participants will be able to: 
1. Describe the role of the AUA Clinical Guidelines for the Surgical Management BPH.
2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.
3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.

Surgical Management Of BPH

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.

CME Available: https://auau.auanet.org/node/31815

At the conclusion of this educational series, participants will be able to:
1. Discuss the impact of SDM on patients and on patient-clinician communication.
2. Identify at least one implementation strategy for using SDM in clinical practice.
3. Apply SDM techniques in a role-playing exercise with other colleagues.
4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases.
5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.

Insight into Race, SDM and the Impact on Access to Quality Care Podcast

Reducing Opioid Exposure in the Perioperative Setting

Optimizing Pre-Operative Care for Patients Undergoing Urologic Surgery

Urolithiasis: Metabolic Evaluation and Medical Management

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.

CME Available: auau.auanet.org/node/31819

At the conclusion of this educational series, participants will be able to:
1. Discuss the impact of SDM on patients and on patient-clinician communication.
2. Identify at least one implementation strategy for using SDM in clinical practice.
3. Apply SDM techniques in a role-playing exercise with other colleagues.
4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases.
5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.

Improving Racial Disparities in Treatment Outcomes Podcast

NMIBC Guidelines

CME Available: https://auau.auanet.org/node/33093

At the conclusion of the activity, participants will be able to:
1. Describe recent developments in the medical management of advanced prostate cancer.
2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
3. Discuss clinical investigations in the treatment of advanced prostate cancer.
4. Analyze the risks and benefits of treatment for advanced prostate cancer.
5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

Acknowledgements
This educational activity is supported by independent educational grants from Astellas, AstraZeneca, Merck, Pfizer, Inc.

Live from AUA2021: Highlights in Advanced Prostate Cancer (2021)

CME Available: https://auau.auanet.org/node/33094

Acknowledgements
This educational activity is supported by an independent educational grant from:
Urovant

Copy of APP Podcast Playlist

User 489017624